DEVELOPMENT OF CLINICAL IMAGING DRUG ENHANCERS (DCIDE)

Release Date:  June 22, 2000

NOTICE:  CA-00-018

National Cancer Institute

The National Cancer Institute (NCI) announces a new program called 
Development of Clinical Imaging Drug Enhancers (DCIDE). DCIDE will make 
available to investigators, on a competitive basis, the preclinical 
development contract resources of NCI.  The goal of DCIDE is the development 
of promising imaging molecular probes or enhancers (contrast agents) that are 
otherwise unlikely to undergo further development leading to Investigational 
New Drug (IND) application.  DCIDE will assist the selected investigators by 
providing or facilitating any (or all) of the preclinical development 
requirements, including, for example, pharmacokinetics, dosimetry, and IND-
directed toxicology.  Assistance may also take the form of direction 
regarding regulatory affairs and access to probes for approved preclinical 
protocols.  For more detailed information, visit the website, 
http://www.nci.nih.gov/bip/dcide.htm

INQUIRIES

Inquiries are encouraged, and the opportunity to clarify issues or answer 
questions is welcome. Inquiries may be directed to:

DCIDE
Biomedical Imaging Program
National Cancer Institute
6130 Executive Blvd, EPN 800
Rockville, MD  20892
Phone: 301-496-9531
Fax: 301-480-5785
Email: [email protected]

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


NIH Office of Extramural Research Logo
   Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) 		  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®